CA2504938C - Compositions and methods for treating or preventing pneumococcal infection - Google Patents

Compositions and methods for treating or preventing pneumococcal infection Download PDF

Info

Publication number
CA2504938C
CA2504938C CA2504938A CA2504938A CA2504938C CA 2504938 C CA2504938 C CA 2504938C CA 2504938 A CA2504938 A CA 2504938A CA 2504938 A CA2504938 A CA 2504938A CA 2504938 C CA2504938 C CA 2504938C
Authority
CA
Canada
Prior art keywords
seq
polypeptide
composition
immune response
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2504938A
Other languages
English (en)
French (fr)
Other versions
CA2504938A1 (en
Inventor
Michael C. Chen
Chuang-Jiun Chiou
Zhongming Li
Dong-Sheng Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synergy America Inc
Original Assignee
Synergy America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy America Inc filed Critical Synergy America Inc
Publication of CA2504938A1 publication Critical patent/CA2504938A1/en
Application granted granted Critical
Publication of CA2504938C publication Critical patent/CA2504938C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2504938A 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection Expired - Lifetime CA2504938C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42449702P 2002-11-07 2002-11-07
US60/424,497 2002-11-07
PCT/US2003/035529 WO2004043376A2 (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Publications (2)

Publication Number Publication Date
CA2504938A1 CA2504938A1 (en) 2004-05-27
CA2504938C true CA2504938C (en) 2011-10-11

Family

ID=32312819

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2504938A Expired - Lifetime CA2504938C (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Country Status (10)

Country Link
US (2) US7217791B2 (enExample)
EP (1) EP1558280B1 (enExample)
JP (3) JP2006506989A (enExample)
KR (1) KR20050086427A (enExample)
CN (1) CN100443116C (enExample)
AU (1) AU2003291365B2 (enExample)
CA (1) CA2504938C (enExample)
ES (1) ES2451620T3 (enExample)
TW (1) TWI315986B (enExample)
WO (1) WO2004043376A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147015A4 (en) 2007-04-13 2011-01-26 Univ Oklahoma State MUTANTS OF CHOLESTERINE-DEPENDED CYTOLYSINES AND USES THEREOF
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
JP6139509B2 (ja) * 2011-04-21 2017-05-31 ザ ロックフェラー ユニバーシティ グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
ES2826393T3 (es) * 2011-10-05 2021-05-18 Univ Rockefeller Lisinas de bacteriófago diméricas
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RS66221B1 (sr) 2014-11-21 2024-12-31 Univ Oklahoma Pneumolizinski mutanti i postupci za njihovu upotrebu
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
WO2020056202A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
WO1995016711A1 (es) * 1993-12-17 1995-06-22 Universidad De Oviedo Anticuerpos contra la neumolisina y sus aplicaciones
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CA2297374A1 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP2053126A1 (en) * 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
BR0016419A (pt) * 1999-12-17 2002-08-20 Método para o aumento das respostas de imunização com relação a vacina do vìrus do herpes simplex

Also Published As

Publication number Publication date
AU2003291365A1 (en) 2004-06-03
US20040213803A1 (en) 2004-10-28
EP1558280A2 (en) 2005-08-03
KR20050086427A (ko) 2005-08-30
JP2012139221A (ja) 2012-07-26
TW200418502A (en) 2004-10-01
EP1558280A4 (en) 2007-08-29
WO2004043376A2 (en) 2004-05-27
JP2006506989A (ja) 2006-03-02
US20080199952A1 (en) 2008-08-21
AU2003291365B2 (en) 2009-06-11
CN1711105A (zh) 2005-12-21
US7585669B2 (en) 2009-09-08
EP1558280B1 (en) 2014-01-08
CA2504938A1 (en) 2004-05-27
TWI315986B (en) 2009-10-21
US7217791B2 (en) 2007-05-15
HK1074005A1 (en) 2005-10-28
CN100443116C (zh) 2008-12-17
JP2010057501A (ja) 2010-03-18
ES2451620T3 (es) 2014-03-28
WO2004043376A3 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
US7585669B2 (en) Compositions and methods for treating or preventing pneumococcal infection
EP1648500B1 (en) Immunogenic compositions for streptococcus pyogenes
US7960535B2 (en) Recombinant lipidated PsaA protein, methods of preparation and use
US9370557B2 (en) Adjuvant compounds
CN101855238B (zh) 融合蛋白疫苗
EP2292645A2 (en) Small Streptococcus pyogenes antigens and their use
US6716432B1 (en) Pneumolysin mutants and pneumococcal vaccines made therefrom
KR20150034192A (ko) 폐렴 연쇄상구균에 의해 유발되는 폐렴에 대한 키메라 단백질 백신
EP2356225A1 (en) GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
US20150079132A1 (en) Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
MX2014010011A (es) Proteinas y composiciones de pilus.
HK1074005B (en) Compositions and methods for treating or preventing pneumococcal infection
CA2488234A1 (en) Immunomodulatory constructs and their uses
AU2003204215B2 (en) Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
Lee et al. Protective immunity and gene expression related to pneumococcal glycoconjugate
HK1250933A1 (en) Immunogenic fusion protein

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231106